Renovaro Biosciences (NASDAQ: RENB) has announced the publication of a peer-reviewed study in the journal Vaccines, showcasing preclinical data on its genetically engineered dendritic cell therapy platform. The study demonstrates the platform's ability to significantly reduce pancreatic tumor burden and activate robust immune responses in humanized mouse models. Key findings include a reduction in tumor weight and volume by up to 81.7%, increased immune cell activity, and selective cytotoxicity against pancreatic tumor cells. The platform's scalable, off-the-shelf approach uses CD34⁺ hematopoietic stem cells, enhancing its clinical utility. Renovaro plans to initiate further preclinical studies across multiple tumor types and explore combination strategies with other therapies. The full study is available in Vaccines.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.